ArticleMolecular therapy : the journal of the American Society of Gene Therapy2026

First-in-human intracisternal dosing of RGX-111 in severe MPS I is well tolerated and generates sustained neurodevelopment without HSCT.

Raymond Y Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.